Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z2NJ
|
|||
| Drug Name |
ASN100
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Hospital-acquired pneumonia [ICD-11: CA40.Z] | Phase 2 | [1] | |
| Ventilator-associated pneumonia [ICD-11: PK81.0] | Phase 2 | [1] | ||
| Company |
Arsanis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Alpha-hemolysin (Stap-coc hly) | Target Info | Modulator | [2] |
| Staphylococcus Five leukocidin toxins (Stap-coc lukF) | Target Info | Modulator | [2] | |
| Reactome | The NLRP3 inflammasome | |||
| WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02940626) Prevention of S. Aureus Pneumonia Study in Heavily Colonized, Mechanically Ventilated Subjects | |||
| REF 2 | Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.